Brain Dopamine Function in Adults With ADHD

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-02-28

Study Completion Date

2009-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to investigate the functional state of dopamine cells and the dopamine transporter in ADHD subjects and controls to assess the effects of chronic methylphenidate treatment on dopamine cell function and dopamine transporter levels in ADHD subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder

NCT02247986

Conduct Disorder Attention Defict Hyperactivity Disorder

WITHDRAWN PHASE1/PHASE2

Methylphenidate in Healthy Young Adults

NCT00815841

Healthy

UNKNOWN PHASE4

Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD

NCT04781972

ADHD - Combined Type

RECRUITING PHASE4

The Effects of Methylphenidate on the Cognitive Function of Older People With Mild Cognitive Impairment

NCT02180529

Mild Cognitive Impairment (MCI)

TERMINATED NA

Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI

NCT03326245

Normal Physiology

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Attention Deficit Hyperactivity Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

methylphenidate

intervention is methylphenidate once daily for 12 months, doses individually titrated

Group Type EXPERIMENTAL

Experimental: methylphenidate treatment

Intervention Type DRUG

subjects received mehtylphenidate treatment for 12 months

No medication

no methylphenidate treatment for non ADHD

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Experimental: methylphenidate treatment

subjects received mehtylphenidate treatment for 12 months

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

methylphenidate once daily for 12 months, doses individually titrated for efficacy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must give informed consent
* Must be between the ages of 18 and 45 years old.
* Must have a confirmed diagnosis of ADHD
* Must have scored on a rating scale that indicate a significant level of symptom severity.
* Must have a childhood history of ADHD must be documented using established test criteria.
* Must have had no previous medication treatment for ADHD except for a short term treatment period of less than three months, which should have occurred at least six months prior to the study.
* Must have an interest in receiving long-term medication treatment for ADHD.

Exclusion Criteria

* Must not test positive for psychoactive drugs during a urine drug screen.
* Must not be pregnant.
* Must not be breastfeeding.
* Must have no past or present history of dependence on alcohol or other drugs of abuse except nicotine or caffeine.
* Must have no past or present history of a psychiatric disorder except ADHD.
* Must have no medical illness that may affect brain function.
* Must not have taken medication that may affect brain function.
* Must not have had head trauma with loss of consciousness (\> 30 minutes).
* Must not have significant anxiety or depression as determined by an established test.
* Must have no history of a significant learning disability.
* Must have no history of cardiovascular or endocrinological disease.
* Must have no history of coagulation disorder.
* Must have no history of sensitivity to lidocaine and/or prilocaine.
* Must have no history of claustrophobia.
* Contraindication to MRI environment (presence of any implanted metallic objects such as cardiac/neural pacemakers, defibrillators, aneurysm clips, certain heart valves, spinal nerve stimulators, artificial joints/limbs, shrapnel/bullets, metal fragments in their eyes, cochlear implants, hearing aids, dental implants).
* Must have no history of glaucoma.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes